Last reviewed 2026-04-23 · How we verify

Group P+P

This drug works by inhibiting the P2Y12 receptor, preventing platelet activation and aggregation.

This drug works by inhibiting the P2Y12 receptor, preventing platelet activation and aggregation. Used for Atrial fibrillation for stroke prevention, Acute coronary syndrome.

At a glance

Mechanism of action

By blocking the P2Y12 receptor, the drug reduces the formation of blood clots, which can cause heart attacks and strokes. This is particularly useful in patients with atrial fibrillation, who are at increased risk of stroke.

Approved indications

• Atrial fibrillation for stroke prevention
• Acute coronary syndrome

Common side effects

• Bleeding
• Thrombocytopenia
• Allergic reactions

Key clinical trials

• Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS (NA)
• Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (PHASE3)
• A Cross-Cultural Randomized Controlled Trial Using a Multi-Level Mentalization Based Prevention Program to Foster Well-Being and Mental Health in Pre-Adolescent Children and Their Families (NA)
• Propofol Versus Sevoflurane Anesthesia on the Intraocular Pressure and Hemodynamics in Patient Undergoing Cyclophotocoagulation (NA)
• The Effect of a Multi-Component Breastfeeding Support Program on Breastfeeding Self-Efficacy and Mother-Infant Bonding in Mothers Following Cesarean Section (NA)
• Parent Intervention to Reduce College Student Drinking and Consequences (NA)
• Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma (PHASE2)
• PREVENT Pilot HPV - Related Cancers Trial (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.